Alain Rolland

Alain Rolland Email and Phone Number

International C-Suite Executive leading start-ups, private and public Pharmaceutical/Biotech companies, from discovery to pre-commercial stage @ AR Pharma Consulting
Alain Rolland's Location
San Diego, California, United States, United States
Alain Rolland's Contact Details

Alain Rolland personal email

n/a
About Alain Rolland

Dr. Rolland is an international executive leading start-up, private and public Pharmaceutical/Biotech companies, from discovery to pre-commercial stage. He had a pioneering career in the discovery and clinical development of novel technologies including nanomedicines for oncology, microspheres for dermatology, gene therapies and DNA vaccines. He co-founded, incorporated, and received seed financing for a start-up and established three biotech organizations from the ground up. He secured early financing, research collaboration and out-licensing with large pharmas and drove several biotech companies from discovery to clinic. He developed and managed P&L, budgets, and resource plans. He defined and established corporate strategy, operational infrastructure, and dynamic teams. He persuasively presented to Board of Directors, investors, analysts, and scientific community.Dr. Rolland identified, negotiated, established, and maintained mission-critical partnerships and licensing agreements. He led partnering activities with Astellas Pharma resulting in upfront cash with milestone payments up to $130M, and supported exclusive license with Eisai for upfront and milestone payments up to $280M. He recently secured a regional pharma licensing deal resulting in up to $300M for upfront and milestone payments. He led multidisciplinary functions and programs, filed more than 12 INDs, orphan drug and fast-track designations, and managed clinical development programs through Phase 3 multi-national studies while developing and enhancing intellectual property portfolio.Dr. Rolland received a Pharm.D, Pharmacokinetics degree, and Ph.D. from School of Pharmacy (Rennes, France). He published 100+ scientific articles and book chapters, edited 3 scientific books, was the founding Editor-in-Chief of Current Pharmaceutical Biotechnology and a member of several scientific societies. He presented at 130+ conferences and is an inventor on 20+ international patents in advanced drug delivery systems, drug/gene targeting and formulation. He was honored by the American Association of Pharmaceutical Scientists as an “AAPS Fellow” for professional excellence and outstanding contributions to the pharmaceutical sciences.Expertise: Vision&Mission; Strategic Planning; Infrastructure Development; Financing; Partnership Development&Preservation; Executive&Talent Recruitment&Development; Budget&Resource Planning; Fast-track Scalable Operations; R&D; Pre-commercialization; Seed, Angel, VC, Institutional Fundraising; IPO; M&A; Business Development; International Patent Estate Growth

Alain Rolland's Current Company Details
AR Pharma Consulting

Ar Pharma Consulting

View
International C-Suite Executive leading start-ups, private and public Pharmaceutical/Biotech companies, from discovery to pre-commercial stage
Employees:
1
Alain Rolland Work Experience Details
  • Ar Pharma Consulting
    Principal
    Ar Pharma Consulting Jul 2014 - Present
    Advise early-stage biotech / pharma companies on corporate strategy, fundraising, partnering, R&D, clinical operations and business development.• Defined and led corporate strategy for an immuno-oncology start-up• Led initial fundraising activities (Seed/pre-Series A) resulting in several million dollars raise through VCs and Angel investors• Established a research collaboration agreement with one of the largest pharma companies• Led out-licensing activities for a regional deal with a large non-US pharma• Drove biotech companies from discovery towards the clinic (CMC, preclinical, regulatory, Quality)• Led business development (US, EU, Japan) for non-US pharma with unique technology platform• Acted as COO for pharma with international (Japan, US, Europe) clinical programs in oncology.• Supported the preparation of IMPD for submission to PMDA in Japan for head and neck cancer trial of an immunotherapeutic biologic product.• Advised French gene therapy company towards IND
    View
  • Emerald Health Pharmaceuticals, Inc.
    Chief Operating Officer, Evp
    Emerald Health Pharmaceuticals, Inc. May 2018 - Feb 2023
    Privately held clinical-stage biopharmaceutical company focused on developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.• Led preclinical and clinical development of synthetic new chemical entities for autoimmune, CNS and other therapeutic applications, including multiple sclerosis, systemic sclerosis, Huntington’s disease and Parkinson’s disease. • Grew patent portfolio of novel molecules to 29 granted and 23 pending international patents• Moved product candidate from very early research stage into clinical stage in <18 months• Established corporate/business infrastructure and operations. Led all phases of product development, nonclinical, CMC, IP, project management, clinical operations • Led business development and Interfaced with Board of Directors.
  • Connect
    Entrepreneur-In-Residence (Eir) - Springboard Program
    Connect Nov 2017 - Dec 2022
    Non-profit organization elevating entrepreneurs by providing educational programming, mentorship, introductions, and access to capital. CONNECT helps innovative companies thrive so they can make a meaningful impact in the development of the San Diego region.
  • Chime Biotherapeutics
    Member Board Of Directors
    Chime Biotherapeutics Jan 2017 - Dec 2017
  • Chime Biotherapeutics
    Chief Executive Officer & President; Co-Founder
    Chime Biotherapeutics Mar 2016 - Nov 2017
    CHIME BioTherapeutics, Inc. is an immuno-oncology company focused on the development of innovative cancer immunotherapies based on the breakthrough concept of recalling and harnessing pre-existing memory immunity to treat a variety of cancers. • Established vision, mission and plans, incorporated company; raised Seed funding, established financials, and managed P&L• Negotiated worldwide exclusive license to intellectual property from non-profit institute (San Diego)• Developed 4-year business and development plan (R&D up through Phase 1b/2 clinical trial)• Introduced CHIME to numerous VCs, with more than 50 meetings presenting the startup• Designated CROs, developed and executed preclinical plans• Signed CDAs with Corporate Ventures for potential funding and JV with Pharma• Presented at JLABS Spotlight and BIO Investor Forum (San Francisco)• Selected for CapitalMatch program at CONNECT, San Diego and became one of a few biotech companies supported by program• Chosen by San Diego Venture Group as one of top 30 semi-finalists for John G. Watson Quick Pitch 2017 competition
  • Augustus Biotarget
    Board Member
    Augustus Biotarget Sep 2014 - Sep 2017
    Non-executive Board member
  • Huya Bioscience International
    Executive Vice President & Chief Scientific Officer
    Huya Bioscience International Apr 2015 - Apr 2017
    San Diego, California, Us
    •Led oncology portfolio with in-licensing evaluation, preclinical and clinical product development, as well as partnering activities. Initially led preclinical and clinical product development, CMC and Quality activities, intellectual property and Japan office•Developed lead product (novel oral small molecule HDAC inhibitor with immunomodulatory activity) with clinical trials in Japan in lymphomas (now on the market). Designed clinical plans for solid tumors•Successfully prepared submissions for Orphan Drug Designation, met with regulatory agencies, and obtained designation in Japan for peripheral T-cell lymphoma•Prepared documentation and met with FDA and PMDA/MHLW•Initiated business development with potential partners resulting in an exclusive license and commercialization agreement for Japan and other Asian countries •Prepared and executed preclinical and clinical development plans and defined strategy for expanding intellectual property•Instrumental in selection and evaluation of several product opportunities for JV in China
    View
  • Vical Incorporated
    Executive Vice President & Corporate Officer
    Vical Incorporated Jan 2009 - Aug 2013
    San Diego, Ca, Us
    Senior Executive Leader & Corporate Officer leading R&D, business development, product development, clinical operations/biostatistics, intellectual property estate as well as operations. Charged with filling VICAL’s pipeline.•Partnered with CEO and CFO on formulating corporate strategy for NASDAQ-traded biopharmaceutical R&D company with DNA technology platform for infectious disease vaccine and cancer immunotherapy product development•Identified and performed due diligence on technologies and new product candidates. Defined and supported product portfolio•Directed strategic and tactical planning, with Corporate and R&D objectives, budget and resources. Defined&implemented organizational infrastructure•Presented technology and product development programs to analysts, investment banks and potential partners resulting in funding and partnerships•Supported Financing activities and Business Development•Led team of 60+ people•Led Clinical Operations/Biostatistics; served as Research Integrity Officer and IACUC Official•Led preclinical and clinical development of new gene-based biopharmaceutical candidates•Oversaw identification of new product concepts, preclinical development and clinical development support•Defined new Stage-Gate Product Discovery and Development Process for enterprise-wide implementation•Transformed organization from technology research to product development, resulting in the filing of several INDsProject Leader for late-stage Development of Allovectin®, a first-in-class cancer immunotherapeutic for stage III and IV metastatic melanoma•Led worldwide Phase 3 trial under a Special Protocol Assessment with FDA •Drove in-house product development and pre-commercialization•Established partnership after Phase 2 trial with Pharma •Member of partnering team for Allovectin®, leading to partnership with Japanese biotech in 2005 for Asian markets•Coordinated patent strategy and filings with Legal department
    View
  • Vical Incorporated
    Senior Vice President, Product Development
    Vical Incorporated Aug 2002 - Dec 2008
    San Diego, Ca, Us
    View
  • Valentis
    Senior Vice President, Preclinical R&D - Head Of The Woodlands Center
    Valentis Mar 2001 - Jun 2002
    Publicly traded (NASDAQ: VLTS) biopharmaceutical company formed in 1999 through merger of GENEMEDICINE (The Woodlands, TX), Megabios (Burlingame, CA) and PolyMASC (London, UK).As an Officer, reporting to President and CEO and as Site Head, defined R&D portfolio, corporate goals, organizational structure, resources and budget. Prepared and implemented strategic and operating plan. Managed preclinical R&D (60+ people) and coordinated with Burlingame, CA headquarters for transfer into clinical development. Supported CEO in financing roadshows. •Led preclinical R&D of product candidates based on gene-based medicines and PEGylated biopharmaceuticals. Identified new product concepts for preclinical development (up to IND filing)•Led technology transfer from UK (from acquired company PolyMASC) to The Woodlands Center; selected and rapidly developed new PEGylated products. Presented technologies and product candidates at scientific conferences and in publications
  • Valentis
    Vice President, R&D
    Valentis Mar 1999 - Feb 2001
    Participated in the merger, rationalization and integration of GENEMEDICINE (The Woodlands, TX) and Megabios (Burlingame, CA) to form VALENTIS, INC., a publicly traded biopharmaceuticals delivery company. As a Corporate Officer, helped define the strategic direction of the merged entity and transition from a technology research to a product-focused Company. Defined and implemented an effective team-based organization to increase efficiency and productivity, and established processes to improve communication. Participated in due diligence to evaluate technologies, products and merger/acquisition candidates.
  • Genemedicine, Inc.
    Vice President, Research
    Genemedicine, Inc. Jun 1993 - Feb 1999
    As GENEMEDICINE’s Executive and Officer of the Company, helped establish the gene medicine product portfolio. Led and managed the Research Function (~45 scientists, including ~20 Ph.D.s) for the creation of technologies to control both the delivery and expression of genes to biological targets (e.g., tumor cells, activated endothelial cells, muscle, antigen presenting cells) using conventional routes of administration. Directed the discovery of technology platforms that enabled several new product opportunities. Helped move a number of products to IND stage and into clinical development. Hired and maintained a worldwide renowned scientific team in the field of gene therapy. Contributed to several publications and patents; represented the Company at International Conferences and business meetings with potential partners. Actively participated in the presentation of the Company and evaluation of M&A candidates.
  • Galderma
    Head Pharmaceutics
    Galderma Jan 1989 - May 1993
    Established and managed the Formulation Department to create and develop novel therapeutic systems for dermatological applications. Responsible for in vitro testing of drug release from the novel formulations (e.g., microspheres, liposomes, patches, nanoparticles) and for studying drug penetration (pathways, kinetics) in animal and human skin, using static and flow-through diffusion cells. Authored several publications and patents; participated in the late-stage development of new topical pharmaceutical products, one now marketed worldwide as Differin(R) gel.
  • Ciba Geigy (Novartis)
    Scientist
    Ciba Geigy (Novartis) Jun 1987 - Dec 1988
    Created and developed a novel nanotechnology (injectable nanoparticulate carrier system). The injectable delivery system was designed to avoid rapid uptake by the mononuclear phagocytic cells, thus enabling its long circulating half-life in blood.

Alain Rolland Skills

Biotechnology Biopharmaceuticals Clinical Development Vaccines Drug Delivery Fda Ind Oncology Pharmaceutical Industry Clinical Trials R&d Infectious Diseases Formulation Regulatory Submissions Strategic Planning Validation Product Development Drug Development In Vitro In Vivo Cancer Cell Pharmaceutics Regulatory Affairs Cro Technology Transfer Commercialization Drug Discovery Lifesciences Gmp Immunology Biologics Glp Project Management Gene Therapy Business Development Clinical Patents Licensing Intellectual Property Due Diligence Analytical Chemistry Mergers And Acquisitions Quality Assurance Research Strategic Partnerships Mergers Nanotechnology Corporate Development Fundraising

Alain Rolland Education Details

  • Columbia Business School
    Columbia Business School
    Transition To General Management
  • Université De Rennes I - School Of Pharmacy
    Université De Rennes I - School Of Pharmacy
    Pharmaceutical Sciences
  • Université De Rennes I - School Of Pharmacy
    Université De Rennes I - School Of Pharmacy
    Pharmacokinetics/Biopharmaceutics
  • Université De Rennes I - School Of Pharmacy
    Université De Rennes I - School Of Pharmacy
    And Administration

Frequently Asked Questions about Alain Rolland

What company does Alain Rolland work for?

Alain Rolland works for Ar Pharma Consulting

What is Alain Rolland's role at the current company?

Alain Rolland's current role is International C-Suite Executive leading start-ups, private and public Pharmaceutical/Biotech companies, from discovery to pre-commercial stage.

What is Alain Rolland's email address?

Alain Rolland's email address is ar****@****ma.life

What is Alain Rolland's direct phone number?

Alain Rolland's direct phone number is +185879*****

What schools did Alain Rolland attend?

Alain Rolland attended Columbia Business School, Université De Rennes I - School Of Pharmacy, Université De Rennes I - School Of Pharmacy, Université De Rennes I - School Of Pharmacy.

What are some of Alain Rolland's interests?

Alain Rolland has interest in Scubadiving, Single Engine Plane Pilot, Reading, Travels, Painting, Horseback Riding, Motorcycle, Movies, Playing And Collecting Flutes.

What skills is Alain Rolland known for?

Alain Rolland has skills like Biotechnology, Biopharmaceuticals, Clinical Development, Vaccines, Drug Delivery, Fda, Ind, Oncology, Pharmaceutical Industry, Clinical Trials, R&d, Infectious Diseases.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.